Thursday, April 16, 2020

The Media Had a Formula for Reporting Sexual Misconduct. Then Joe Biden Was Accused.







BRANKO MARCETIC







For nearly three weeks after it surfaced, Tara Reade’s sexual assault allegation against Joe Biden was ignored or downplayed in the media. A Jacobin analysis shows that she’s been covered unlike any other accuser in the post–Me Too era.




https://jacobinmag.com/2020/04/joe-biden-tara-reade-sexual-assault-allegation-media







Nearly a year ago, journalist E. Jean Carroll wrote an essay in which she publicly accused the president of the United States of sexually assaulting her in a dressing room more than two decades ago. The accused, or rather, his press team, called it “false.” There was no evidence Carroll could point to — how could there be? — except for two people she had told at the time, who confirmed the memory to New York magazine.

The story was left off the front pages of the nation’s top newspapers, including the New York Times, which banished it to its book section, and was nowhere to be found among the 164 stories on the paper’s homepage (executive editor Dean Baquet later admitted the Times had been “overly cautious” and had underplayed the story). On TV, the Sunday shows largely gave it a pass. The most powerful man in the world had been credibly accused of sexual assault, and no one seemed to care.

Fast-forward nine months later. A woman has come forward to publicly accuse the frontrunner to become the next president of the United States of sexually assaulting her in a Senate office more than two decades ago. The accused’s team has called the story “false.” There is no evidence, except the two people still living whom the accuser confided in at the time, who confirmed to the Intercept their memory of being told the story.

The result has again been media silence, only this time with a twist. Because not only has Tara Reade and her allegation against Democratic frontrunner and now presumptive nominee Joe Biden inexplicably received perhaps the least mainstream media attention of any high-profile sexual assault allegation of the past three years, but it is some of the news outlets most critical of the media’s treatment of Carroll and other survivors who are choosing to ignore the story — or, in some cases, undermining their gravity.

After Hillary Clinton’s loss, liberals harshly criticized the press for reporting on hacked Democratic National Committee and Clinton campaign emails, whose revelations damaged her campaign against Trump. The Times itself charged that every major news outlet became “a de facto instrument of Russian intelligence” for doing their jobs. Some journalists have publicly questioned their decision to report negatively on Trump’s opposition, such as the Times’s own Amy Chozik.

“The choice wasn’t between getting it right and getting it first,” the Washington Post’s Aaron Blake reflected in December 2016 on reporting about the leaks; “it was between getting it first and playing to the potential agenda of an anonymous source — a source who could have been an adversarial world power such as Russia or a more nefarious source or just some random hacker.”

Donald Trump is an odious figure who deserves scorn and criticism. But as one observes the demonstrably different standards the media have applied to a sexual assault allegation against the man many see as his best-placed rival, it’s hard not to suspect that parts of the press have unhealthily internalized partisan accusations that their reporting put him in power.
A Deafening Silence

The mainstream media silence around Reade was abruptly broken on Sunday, when the New York Times reported on her allegation, leading to a flood of stories from other mainstream outlets. But it’s worth taking stock of where the situation was at the end of last week.

Two weeks after the Intercept first broke the story, and after the world first heard the details of what allegedly happened to Reade in interviews with Katie Halper and Rising’s Krystal Ball, the national, mainstream outlets that had covered Reade’s allegation could be counted squarely on both hands: Yahoo News, Newsweek, the Huffington Post, Vox, the Economist, the Guardian, and Democracy Now!, which interviewed Reade.

None of the country’s biggest newspapers had covered the allegation whatsoever, including the New York Times, Wall Street Journal, Los Angeles Times, Chicago Tribune, Boston Globe, USA Today and the Washington Post. Only the latter had even mentioned Reade’s allegation: a single time, in a reader question about the odds of New York governor Andrew Cuomo becoming the nominee “in light of the Tara Reade bombshell”; in his answer, the Post’s Aaron Blake — the same person who years earlier mused that accurate reporting that potentially serves a pro-Trump agenda “adds a whole new element to the journalistic equation” — avoided even referencing the allegation. Reporting about it was absent from Politico, too.

Nor was it covered by CNN or MSNBC, in either their political coverage or interviews with the former vice president. According to Newsbusters, a right-wing media watchdog, Biden sat for at least four interviews with cable news hosts in the six days that followed the allegation, including an hour-long CNN town hall. None of the forty-one questions he fielded were about the allegation.

Indeed, one of the ironies of Reade’s story is that while the mainstream press ignored the story, it was being extensively covered by right-wing media, including Fox News, the Washington Examiner, the Washington Times, Reason, and the Daily Wire. Where the past three years have seen mainstream and left-leaning news outlets devote increasing resources to reporting on sexual misconduct by powerful men and grant survivors a larger platform, right-wing outlets such as these have been openly skeptical, even disdainful, when accusations have targeted conservatives.

With a powerful Democrat now under the spotlight, the roles have seemingly reversed. And much of the conservative coverage of Reade’s story is now aimed at hitting mainstream outlets for hypocrisy.
The Standard Last Year

Compared to the dearth of coverage of Reade, Carroll’s allegation was treated like the story of the century. Carroll may have inexplicably been relegated to the New York Times book section, but the paper at least devoted an entire piece to it the day it broke. Under criticism for under-covering the story, the Times followed up six days later with a much more in-depth, prominent feature on it. Even as four of the “big five” TV networks left her off their coverage in the days that followed her essay, Carroll’s story was nonetheless covered by MSNBC, NBC News’ online portal, NPR, the Atlantic, and Vanity Fair, among others.

By contrast, until Sunday, none of these outlets so much as mentioned the existence of Reade’s allegation. Some still haven’t.

Of the major newspapers named above that failed to cover Reade’s allegation two weeks later, all but one reported on Carroll’s the same day it was revealed: the New York Times, the Washington Post, the Wall Street Journal, the LA Times, the Tribune, and the Boston Globe, typically after interviewing Carroll and getting corroboration from her friend. Often, they ran follow-up pieces in the days after. USA Today ran its piece on Carroll’s allegation a day after it first broke. In the days and months since, Carroll’s story received a steady amount of media attention, and she was invited onto CNN three days after her story broke. By June 26, five days after the story first ran, it was fodder for late-night talk show hosts.

At the time, the muted response to Carroll’s allegation saw news outlets big and small noting, sometimes angrily, the lack of media coverage that greeted it. The fact that Carroll’s story didn’t receive the “wall-to-wall coverage” comedian Samantha Bee felt it deserved led her to launch a celebrated takedown of the press within a week of the story breaking. Others followed suit.

“E. Jean Carroll accused the president of sexual assault — and the media didn’t seem to care,” wrote Vanity Fair.

“Why Has the Reaction to a Rape Allegation Against the President Been So Muted?” asked New York magazine, which had broken the story.

Similar pieces have been written about Reade’s allegation, but they’ve been limited to outlets that covered it from the start, such as the Hill and Huffington Post. The outlets that railed against Carroll’s relative erasure from the press failed to muster the same outrage about Reade, who received far less attention.

MSNBC’s silence particularly stands out. It was the Democrat-aligned network that first allowed Carroll to recount her story, appearing with Joy Reid, who charged that the media had “relatively buried” it, and thundered that “in any other universe, in any other presidency, in any other news cycle, E. Jean Carroll’s bombshell revelations against the sitting president of the United States would have been the lead story all week long, as soon as they dropped.” Elsewhere, MSNBC host Joe Scarborough complained that “there are a lot of Democrats out there that are saying, ‘Wait a second. Joe Biden placed his hands on a woman’s shoulders, and that got more press coverage on every Sunday show than [Carroll’s accusations].’” (“How balanced do you have to be when one side is irrational?” Scarborough once said about his attacks on Trump.)

MSNBC finally reported on Reade’s allegation about Biden on Sunday, ending the report by “underscor[ing] that the current sitting president has also faced multiple accusations that he denies.”

Beyond Carroll’s story, it’s difficult to comport the lack of Reade’s coverage with how the stories of other accusers of powerful men have been treated in the media. Take Christine Blasey Ford and her accusation against Supreme Court justice Brett Kavanaugh, another allegation whose existence, as with Reade, was first revealed by the Intercept’s Ryan Grim, who reported on a letter being withheld from the Judiciary Committee.

Two days later, Ronan Farrow first revealed the content of that letter for the New Yorker, namely that it accused Kavanaugh of holding down a girl at a party and trying to force himself on her as a high-school student in the early 1980s. The allegation was immediately and widely covered across the media the same day Farrow’s piece ran, with outlets ranging from the New York Times, USA Today, and the Guardian to CNN, the Washington Post, and NPR re-reporting its details. At the time, several of the key elements that have lent credibility to Reade’s allegation were absent: Blasey Ford’s identity wasn’t known, no journalist had spoken to her, and no one had yet corroborated her accusation.
The Times Weighs In

The treatment of Reade’s story by the New York Times, the first major paper to even acknowledge the existence of Reade or her allegation, is particularly difficult to square with its coverage of other accusers.

One is the time frame. Though the paper says it “began reporting on her account and seeking corroboration” as soon as the Intercept broke the story, it ultimately took the Times nearly three weeks to put out a report. By contrast, the paper’s report on Carroll dropped the same day that the rest of the world found out about it, and the same goes for its story on Blasey Ford’s letter.

Some have defended the Times, arguing that it takes time to get the reporting right. But while the paper no doubt needed time to interview dozens of former Biden staffers for its in-depth evaluation of Reade’s allegation, it could’ve reported on the existence of the allegation at the time it surfaced by simply speaking to Reade’s witnesses. This is exactly what it did in the case of Carroll and Trump, writing an initial report after interviewing the two friends Carroll confided in at the time, before releasing a longer, more detailed profile of Carroll six days later that featured the testimony of many more interviewees.

It’s even harder to square with the Times’s reporting on the accusation against Kavanaugh: the paper reported on the allegations the day the broke, basing its report entirely on an anonymous letter the paper admitted it hadn’t even seen.

The content also raises eyebrows. Though the most newsworthy part of the Times’s report is that it further corroborates Reade’s story — there is now a third person who recalls Reade telling her about it at the time, and two former interns confirm Reade was suddenly pulled off her duties, as she has repeatedly claimed — the paper instead framed the piece around denials by Biden’s staff, most of whom were never told about the incident in the first place. “Former Senate office staff members do not recall such an incident,” the paper concludes in the article’s subhead.

Mystifyingly, the paper devotes two paragraphs to detailing Trump’s history of sexual misconduct, which the paper informs readers “went far beyond the accusations against Mr. Biden.”

It’s a stark contrast to the sympathetic treatment the Times offered Kavanaugh accuser Deborah Ramirez, who the Times reported on two days after her allegation surfaced, without interviewing her or being able to find a witness (the New Yorker confirmed one fellow student remembered the incident in question, and a year later the Times published a more detailed report corroborating it further). Unlike when covering Reade, denials from those loyal to the accused were relegated to the bottom of the piece, which centered Ramirez and her story, and made her struggle to find a corroborating witness part of a tender opening to the piece.

Nonetheless, the Times piece opened the floodgates in the mainstream press, as several other outlets apparently spontaneously concluded their own weeks-long investigations into the allegation on the same day, including the Washington Post and NBC News.

When Kavanaugh was accused in 2018, all three of these outlets had reported on the allegation against him the day it broke, when the only source was a letter none of the reporters involved had even seen; when it was Biden, they took nearly three weeks, despite the existence of two people corroborating the accuser’s story from the beginning.
Doubt From Unexpected Quarters

While most outlets chose to simply ignore Reade, others took a different tack: playing down or even attempting to discredit her allegation. In an added twist, it’s some of the most vocal forums of liberal feminism who took on this task.

Some simply ignored it. New York magazine, which had broken the Carroll story and noted its lack of media coverage, didn’t report on Reade’s story, only updating a year-old round-up of Biden accusers on Sunday with Reade’s new allegation. It published a standalone piece later that day.

Others have taken an explicitly skeptical tone. Salon’s Amanda Marcotte wrote a piece purporting to set the record straight on the controversy, arguing the press was rightly taking “a slow and careful approach.” Various “red flags” in Reade’s story — namely, the fact that she added details to her story over time, was publicly complimentary of Biden, supported some of his rivals, and that his longtime staff issued denials — mean what’s “likely driving the silence — so far — is a genuine reluctance to dive into a story that contains such a high number of complicating factors and proves difficult to pin down.”

Marcotte was less sanguine when the accuser in question was Carroll and the accused was Donald Trump. “Trump accused of rape, major media yawns,” she wrote only three days after Carroll’s story broke. For Marcotte, that case was “an incredibly serious story, deserving of at least the wall-to-wall coverage and outrage that greeted” the Clinton-Lewinsky scandal, concluding that “the main reason the media is underplaying this story is that women are still not taken seriously as full citizens and participants in our democracy.” Carroll’s story was not a “he said/she said,” she wrote, but “backed by significant evidence,” citing the friends Carroll had spoken to at the time — an aspect Marcotte treats with far less significance in the Reade case.

Marcotte’s reasoning that “red flags” in Reade’s story justify media inaction is difficult to comport with how “imperfect” survivors have been treated by the press in the past, including by Marcotte herself. Inconsistencies and gaps in Blasey Ford’s testimony hadn’t stopped Marcotte from deciding she had been an “oasis of clear-headed competence, decency and genuine commitment to the value of truth and civic duty.”

The fact that Reade’s “public statements about Biden were entirely positive” was a red flag for Marcotte that muddied the waters for reporters. Elsewhere, Marcotte has cited Trump accuser Jill Harth, without taking the time to weigh the “red flags” of Harth’s own personal history, which included dating Trump after he attempted to rape her, and a year earlier sending his campaign emails asking for a job and stating that she was “definitely on Team Trump.”

It was a similar situation with feminist outlet Jezebel, which, unlike its treatment of presidential candidate Trump’s sexual misconduct, took six days to cover Reade’s allegation, and has only done so once. Though acknowledging Reade’s story was “both harrowing and credible,” Jezebel chose to frame its coverage of the bombshell not around a leading presidential candidate’s alleged assault of a staffer, but around a critique of Halper’s handling of the story even as it acknowledges Halper had confirmed Reade’s account with her brother and friend — the core of what Reade is alleging.

Jezebel has taken a very different approach to reporting on accusations made against other powerful men. Just four days earlier, it had quickly reported on a rape allegation against rapper French Montana, based entirely on anonymous allegations made in a lawsuit. The same applies to other political figures already mentioned. Jezebel wrote early and often on the accusations against Kavanaugh, including when Blasey Ford’s accusation was still an anonymously penned, uncorroborated letter reporters hadn’t actually seen. It likewise covered Ramirez’s allegation the day it was first reported, at a time when the New Yorker was only able to find a single classmate to corroborate it — less than the “lack of corroboration” the outlet now claims for Reade’s story.

And it raged at the “absence of effect” and lack of “attention and outrage” that greeted Carroll’s story, excoriating the Times for its cautious treatment of the story even though the paper had “taken the time to re-corroborate Carroll’s story with the two friends she spoke to after the alleged assault — a detail that New York had already explicitly, prominently fact-checked.” As with Marcotte, what was significant evidence for Jezebel when Trump was accused became buried by handwringing when it was Biden in question.

Despairing at the lack of coverage for Carroll, the outlet had waved away attempts to justify media silence on the issue. The words and actions of a powerful political figure, it concluded,


regardless of how petty, how baseless — will always remain the domain of news, while the words and recounting of the woman he allegedly assaulted — no matter how exactingly constructed her story, how righteous her message, how broad her platform — will remain fodder for analysis.

A year later, it reads as an indictment of the treatment Jezebel itself has given Reade’s story.

Jacobin sent the Times, Marcotte, and Jezebel a detailed list of questions about what the editorial thought process was behind covering Reade’s allegations differently to previous accusers. Only Jezebel responded, though it declined to answer any of the questions:


Jezebel wrote about and reported on Reade’s credible story, as we did with Christine Blasey Ford, E. Jean Carroll, an anonymous Al Franken accuser, and countless others. Your questions suggest that there was some ulterior motive for not covering Reade’s story with more frequency, which is both disingenuous and insulting.
The Wages of Silence

It’s fair to say that Tara Reade has been treated unlike any high-profile accuser of the past three years.

While previous accusers of powerful men were widely covered in mainstream print, digital, and TV media, only a handful of outlets trickled out stories on Reade’s allegation. While widespread coverage greeted past accusers almost instantly, it has taken nearly three weeks for Reade’s mere existence to be acknowledged by a single major newspaper. And while there was no shortage of articles fiercely criticizing the media’s underplaying of another survivor’s story, those same critics have now taken to justifying the even more egregious media silence over Reade’s.

Defenders of this particular media silence are right to insist on vetting accusers’ claims, no matter how long it takes. Yet Reade’s story started out with as much corroboration as previous claims that saw no similar delay in reporting — in fact, it had more than several key cases.

“The model going forward will likely involve Republican media covering Democratic corruption and Democratic media covering Republican corruption,” Matt Taibbi lamented in August 2016.

With Reade’s case, we appear to be seeing that playing out in real time. And that approach will fail not only political discourse, but future accusers of sufficiently powerful men or women.


Ana Kasparian on why Tara Reade's allegations against Joe Biden matter



https://www.youtube.com/watch?v=ZZa1dt1aAK8&feature


























On Italy & the EU after the Eurogroup of 9th April – fanpage.it (English version)



Yanis Varoufakis



The debate about the economic consequences of the Coronavirus pandemic has already begun: what do you think is easier to happen? Will it be a momentary crisis or a crisis destined to change our economic system forever?
Neither. The consequences will be harsh and will not disappear any time soon. But, it will not, on its own, change the way capitalism works – even though, it is true, commentators revisit important policy changes, e.g. Universal Basic Income.
We must not forget that in times of crisis all sorts of progressive ideas are floated. For example, in 2009 the G20 even discussed the prospect of rejigging global finance in a manner that reflecting John Maynard Keynes' splendid proposal for an International Clearing Union. Today, under lockdown, we have had a revival 'helicopter money' as a possible source of funding a Universal Basic Income. But, as in 2009 so too now, ideas that are not immediately enacted will be allowed to fade as the oligarchy-without-borders recovers and regains full control of the public debate. So, no, I do not think that these progressive ideas will be implemented by our present rulers. But, there is hope that they will be implemented once this huge new turn of the post-2008 crisis creates new political movements that can, potentially, take over from the current establishment. It may not be hugely likely but it seems to me the only path to something genuinely progressive.
A year after the reopening, what world will we find ourselves in? Will it be a more or less unequal world, a more or less free world, more or less aware of environmental issues, more or less open?
The world will be an unhappier and a much more divided place. In Europe countries that were hit less both by Covid-19 and by economic depression will emerge much stronger relative to countries like Italy. So, on the one hand, Europe will emerge weaker as a whole, the imbalances undermining the Union will emerge hugely reinforced.
Do you think there is a privacy and surveillance issue that arises in Europe?
We had these issues before the pandemic hit. These concerns will grow further. When you give rulers a taste of great power to know, and to control, what citizens do it is hard to end their addiction. This is why DiEM25 is well placed to combat these encroachments into our civil liberties: Because, from 2016, we started thinking about transparency, Europe’s technological sovereignty and ways to democratise data.
Yesterday there was the Eurogroup in which the measures were taken to stem the post-pandemic crisis in Europe: what do you think of these measures?
They will go down in history as a major defeat for Europe and proof that the Eurozone’s managers are unable to contribute to Europe’s shared prosperity. In contrast to the US, the UK and Japan where 6% of total income was injected into the economy as direct funds and debt write-offs, the Eurozone’s decision involved a pitiful 0.22% of pure injections, the rest being irrelevant loans. Our finance ministers should hang their heads in shame.
Is this the moment to raise the issue of the different tax burden in Europe? There are countries like Holland, Ireland and Luxembourg where taxation is practically zero. Could the post-pandemic recovery not be financed even with a corporal tax?
No, this is the moment for sensible Europeans to realise that there is no such thing as a European Union. All we have left is a sad and dangerous European Disunion in which policy is re-nationalised and where our common institutions are only allowed to do things that benefit the oligarchy-without-frontiers.
In your opinion, are Eurobonds a fair battle to fight? Or is it an impossible challenge?
Eurobonds are essential. Without them the Eurozone will either die or become a cruel cage of austerity in which our people will languish? Are Eurobonds feasible? Of course. But only if the Italian, Greek, Spanish etc. Prime Minister is prepared to veto everything in the European Council meeting until and unless a Eurobond of at least €1 trillion, and with a 30 year maturity, is issued.
Do you think Europe will survive this post-pandemic crisis? In Italy anti-European sentiments are increasingly widespread ... You recently published Euroleaks, audio files of the recordings of the Eurogroup meetings from 2015 onwards: what do those recordings tell? Why aren't those meetings recorded?
They are not recorded because the powerful do not want you to know how they reach anti-European decisions behind closed doors in your name. Is Europe going to survive? Sure it will. Will it become a realm of shared prosperity? Certainly not, unless we veto the current idiotic policies. Will the EU survive? It certainly does not deserve to survive, if our leaders continue doing the same over and over again. But, it might survive at the expense of a majority of people in a majority of countries. That’s why DiEM25 is calling upon progressives to unite transnationally behind an agenda for the many everywhere.

For the Italian version as published in fanpage.it click here


Serology-based tests for COVID-19













https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html







Serology testing for SARS-CoV-2 is at increased demand in order to better quantify the number of cases of COVID-19, including those that may be asymptomatic or have recovered. Serology tests are blood-based tests that can be used to identify whether people have been exposed to a particular pathogen by looking at their immune response. In contrast, the RT-PCR tests currently being used globally to diagnose cases of COVID-19 can only indicate the presence of viral material during infection and will not indicate if a person was infected and subsequently recovered. These tests can give greater detail into the prevalence of a disease in a population by identifying individuals who have developed antibodies to the virus.

This page serves to provide up to date information on serology tests that are in development or available for use. Importantly, many of these tests have been approved for research use only, which indicates that they are not yet approved for use as a public health diagnostic tool or for at-home diagnosis. Some of these tests may move forward to approval for diagnostic use, while others may be appropriate for research only.

Disclaimer
This website is updated twice weekly, and only includes tests for which data and documentation is available and for which their stated intended use aligns with their FDA (or relevant national regulatory body) status. This site does not include tests that are in subsection IV.D of the FDA Policy for Diagnostic Tests for Coronavirus Disease-2019, as these have not been approved by the FDA and may not have indicated to the FDA that they are pursuing EUA approval. This site is not intended to be used as a reference for funding or grant proposals. Non-inclusion in this list should not be interpreted as judgement on validity or legitimacy of tests.

This page was last updated on April 15, 2020.



Navigation:
Description of types of serology assays (RDT, ELISA, neutralization, etc.), including uses and benefits
Tests that have been approved for diagnostic use in the United States
Tests that have been approved for diagnostic use in other countries
Tests that have been approved for research or surveillance purposes only
Tests that are still in development


Description of types of serology assays

Rapid diagnostic test (RDT): This is typically a qualitative (positive or negative) lateral flow assay that is small, portable, and can be used at point of care (POC). These tests may use blood samples from a finger prick, saliva samples, or nasal swab fluids. RDTs are often similar to pregnancy tests, in that the test shows the user colored lines to indicate positive or negative results. In the context of COVID-19, these tests most frequently test for patient antibodies (IgG and IgM), or viral antigen. In some cases, it can be beneficial to measure baseline (before infection) of IgG and IgM titers.

Enzyme-linked immunosorbent assay (ELISA): This test can be qualitative or quantitative and is generally a lab-based test. These tests usually use whole blood, plasma, or serum samples from patients. The test relies on a plate that is coated with a viral protein of interest, such as Spike protein. Patient samples are then incubated with the protein, and if the patient has antibodies to the viral protein they bind together. The bound antibody-protein complex can then be detected with another wash of antibodies that produce a color or fluorescent-based readout. In the contest of COVID-19, these tests most frequently test for patient antibodies (IgG and IgM).

Neutralization assay: This test relies on patient antibodies to prevent viral infection of cells in a lab setting. Neutralization assays can tell researchers if a patient has antibodies that are active and effective against the virus, even if they have already cleared the infection. These tests require whole blood, serum, or plasma samples from the patient. Neutralization assays depend on cell culture, a lab-based method of culturing cells that allow SARS-CoV-2 growth (like VeroE6 cells). When virus and cells are grown with decreasing concentrations of patient antibodies, researchers can visualize and quantify how many antibodies in the patient serum are able to block virus replication. This blocking action can happen through the antibody binding to an important cell entry protein on the virus, for example.
Type of test Time to results What it tells us What it cannot tell us Figure
Rapid diagnostic test (RDT) 10-30 minutes The presence or absence (qualitative) of antibodies against the virus present in patient serum. The quantifiable amount of antibodies in the patient serum, or if these antibodies are able to protect against future infection RDT figure
Enzyme linked immunosorbent assay (ELISA) 1-5 hours The presence or absence (quantitative) of antibodies against the virus present in patient serum. If the antibodies are able to protect against future infection. ELISA figure
Neutralization assay 3-5 days The presence of active antibodies in patient serum that are able to inhibit virus growth ex vivo, in a cell culture system. Indicates if the patient is protected against future infection. It may miss antibodies to viral proteins that are not involved in replication. PRNT figure





Tests that have been approved for diagnostic use in the United States
Country of development US/China
Type of Serological Test RDT
Authors/Company Cellex Inc.
Description RDT, lateral flow assay, which detects IgM and IgG to the nucelocapside protein of SARS-CoV-2. The sensitivity is 93.8% and specificity is 95.6%, when tested at 2 Chinese hospitals in a total of 128 COVID19 positive patients, and 250 COVID19 negative patients (as detected by RT-qPCR).
Phase of development Approved by FDA for EUA on diagnostics, has CE approval
Proposed release available for purchase by research labs/healthcare providers (product number 5513)
Date April 1, 2020



Country of development USA
Type of Serological Test RDT
Authors/Company ChemBio
Description This test detects IgM and IgG antibodies to the nucleocapsid (N) protein of SARS-CoV-2. Sensitivity and specificity values were not released.
Phase of development Approved for EUA by the FDA
Proposed release April 14, 2020
Date April 15, 2020



Country of development USA
Type of Serological Test Modified ELISA
Authors/Company VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack/Total Calibrator (Ortho Clinical Diagnostics)
Description This test is a proprietary ELISA, and detects total IgM and IgG, but does not discern between the two. Sensitivity and specificity have not been disclosed. This must be used on the platform VITROS® XT 7600 Integrated System, the VITROS® 3600 Immunodiagnostic System, the VITROS® 5600 Integrated System and VITROS® ECi/ECiQ Immunodiagnostic systems.
Phase of development Approved for EUA by the FDA
Proposed release April 14, 2020
Date April 15, 2020





Tests that have been approved for diagnostic use in other countries
Country of development US/China
Type of Serological Test RDT, solid phase immunochromatographic assay
Authors/Company Aytu Biosciences/Orient Gene Biotech
Description The (COVID-19) IgG/IgM Rapid Test will assay patient antibodies to SARS-CoV-2 from blood or plasma samples. The sensitivity is 87.9% and specificity is 100% for IgG, and for IgM it is 97.2% and 100%, respectively.
Phase of development CE approved, used in China in clinical settings, awaiting FDA approval
Proposed release Shipments should be ready by early April
Date March 10, 2020



Country of development US/China
Type of Serological Test Proprietary
Authors/Company ScanWell Health/INNOVITA
Description This kit is for detection of IgG and IgM for SARS-CoV-2 in the blood, taking only 15 minutes, and is an at-home test. The test has 87.3% sensitivity and 100% specificity.
Phase of development Cleared by China's National Medical Products Administration (NMPA), and pending approval by US FDA
Proposed release 6-8 weeks (May 1 to May 15), depending on FDA approval date
Date March 20, 2020



Country of development Singapore
Type of Serological Test Not explicity stated, though their "gold standard" is a neutralization assay
Authors/Company Singapore/ Wang Lab
Description The Wang lab developed two tests. One, which has about 90% sensitivity, is rapid and uses recombinant viral proteins to detect reactive antibodies. The second is their "gold standard" and utilizes a viral neutralization assay but takes 3-5 days.
Phase of development Deployed in Singapore
Proposed release Not stated
Date March 1, 2020



Country of development China
Type of Serological Test Lateral flow assay (RDT)
Authors/Company Guangzhou Wondfo Biotech Co Ltd
Description Wondfo SARS-CoV-2 Antibody Test, which is a lateral flow assay that assays patient IgG and IgM. The article did not specify target antigens, sensitivity, or specificity
Phase of development CE/IVD, approved by NMPA in China for point of care testing
Proposed release CE/IVD in the EU
Date Feb. 22, 2020



Country of development China
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company Guangdong Hecin-Scientific
Description Tests for IgM against SARS-CoV-2.
Phase of development Cleared by China's National Medical Products Administration (NMPA)
Proposed release Approved for use in China
Date Feb. 22, 2020



Country of development China
Type of Serological Test RDT
Authors/Company Dynamiker
Description The test, DNK-1419-1, assays for patient IgG and IgM with 92% accuracy.
Phase of development The NMPA has approved it in the 7th edition of Diagnostic and treatment protocol of COVID-19
Proposed release Used in China, no other approvals to date
Date Date not given



Country of development The Republic of Korea
Type of Serological Test RDT
Authors/Company SD Biosensor
Description US supplier Henry Schein will distribute the test for IVD use only
Phase of development Approved for diagnostic us outside the US, Research use only in US
Proposed release 2-3 weeks
Date March 26, 2020



Country of development US
Type of Serological Test ELISA
Authors/Company MayoClinic/University of Minnesota
Description MayoClinic is developing an ELISA to test for antibodies to SARS-CoV-2. The types of antibodies are not stated, nor is sensitivity or specificity.
Phase of development Clinical
Proposed release April 6, 2020
Date April 1, 2020



Country of development USA
Type of Serological Test RDT
Authors/Company Advaite
Description RapCov Rapid COVID-19 Test is an in vitro diagnostic test for IgM and IgG antibodies. In a study with 18 healthy and 18 COVID-19 positive patients, the sensitivity was 89% and specificity was 100%. It should be noted that "specificity" was only performed on healthy patient samples, not patient samples from related viruses. Further testing is necessary to validate the test. It is currently being used to study community prevalence in Chester County, PA. https://advaite.com/press-release/advaite-deploys-covid-19-rapid-antibody-test-kits-to-chester-county-and-collaborates-with-pennsylvania-companies-to-scale-up-manufacturing/
Phase of development Research use only (IVD), not approved for diagnostic use. This company was not found on any FDA categorization of tests
Proposed release April 2020
Date April 6, 2020





Tests that have been approved for research or surveillance purposes only
Country of development US
Type of Serological Test ELISA
Authors/Company Epitope Diagnostics, Ltd
Description KT-1032 tests for IgG to SARS-CoV-2, while KT-1033 tests for IgM to SARS-CoV-2. The kits do not state the antigens of interest.
Phase of development Approved by FDA, for clinical use only and for research use. Not for at home testing. The test itself has not been evaluated by the FDA
Proposed release Ongoing
Date March 3, 2020



Country of development US
Type of Serological Test RDT
Authors/Company CTK Biotech
Description The test, COVID-19 IgG/IgM Rapid Test, tests for patient IgG and IgM in a lateral flow assay.
Phase of development Not approved for use in the US, but available for purchase by research labs/healthcare providers
Proposed release available for purchase by research labs/healthcare providers and export out of the US
Date March 12, 2020



Country of development US
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company BioMedomics
Description This assay detects patient antibodies, IgG and IgM, on a lateral flow assay. It uses a recombinant viral antigen, though it does not state the specific antigen. The test is a 3 line read-out, one line for a control, one line to detect IgM, and one to detect IgG. Three lines indicates the patient has both IgG and IgM.
Phase of development CE/IVD, approved by FDA but only for research use
Proposed release CE/IVD, available for purchase by research labs/healthcare providers in the US, but only for research use
Date March 16, 2020



Country of development US
Type of Serological Test RDT
Authors/Company Ray Biotech
Description This test, the Coronavirus (COVID-19) IgM/IgG Rapid Test Kit, detects patient IgM and IgG to SARS-CoV-2 in patient blood samples. It detects antibodies against the viral N protein.
Phase of development CE/IVD, approved for research use only in the US. Approved for research use under FDA EUA.
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date March 19, 2020



Country of development US
Type of Serological Test ELISA
Authors/Company Creative Diagnostics
Description Kit DEIASL019 detects patient IgG for SARS-CoV-2, and uses the whole virus lysate as the antibody binding target. The reported sensitivity and specificity are 100% (from 16 and 30 samples, respectively). The DEIA2020 kit only tests for patient IgG that reacts to N protein.
Phase of development Not approved for diagnostic use; for research use only
Proposed release available for purchase by research labs/healthcare providers, but not for diagnostic use
Date March 20, 2020



Country of development US
Type of Serological Test ELISA
Authors/Company Eagle Biosciences
Description This company has two kits, one (KTR-1032) which targets patient IgG, and one (KTR-1033) that targets IgM. The target antigen is an "HRP-labeled-COVID-19 antigen." They did not list sensitivity or specificity
Phase of development Research use only, CE/IVD outside the US
Proposed release available for purchase by research labs/healthcare providers, but not for diagnostic use
Date Date not given



Country of development China/US
Type of Serological Test RDT
Authors/Company Sure Biotech
Description The Coronavirus Rapid Test assays for IgG and IgM antibody in blood or plasma samples, with 92-96% accuracy.
Phase of development CE approved
Proposed release available for purchase by research labs/healthcare providers, CE approved
Date Feb. 2020



Country of development China/US
Type of Serological Test RDT, immunofluorescence, colloidal gold
Authors/Company BioEasy/Shenzhen BioEasy Biotechnology Co.
Description There are three tests: 1) the 2019 nCoV Ag test, which assays sputum or nasal swabs for SARS-CoV-2 antigens and gives a fluorometric read out, 2) the 2019-nCoV Ag GICA test, which uses colloidal gold, and 3) the 2019 nCoV IgG/IgM GICA rapid test which assays for patient antibodies to the virus from blood samples
Phase of development CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date Date not given



Country of development The Republic of Korea
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company Sugentech
Description This test is a colloidal gold lateral flow assay that can be read in 10 minutes, and measures presence of patient IgG and IgM.
Phase of development CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date Date not given



Country of development The Republic of Korea
Type of Serological Test RDT
Authors/Company SD Biosensor
Description This company currently offers 3 tests. 1) The Standard Q COVID-19 IgM/IgG Duo which tests for both IgG and IgM patient antibodies to SARS-CoV-2. Sensitivity was 82% and specificity was 97% (based on data from 30 healthy donors and 33 COVID-19 positive individuals. 2) Standard Q COVID-19 Ag, which detects virus antigen from nasopharyngeal swabs, and 3) Standard F COVID-19 Ag FIA, which detects viral N protein present in nasopharyngeal swabs in a fluorescence based assay.
Phase of development Korea EUA approved
Proposed release available for purchase by research labs/healthcare providers, but not for diagnostic use
Date Date not given



Country of development Singapore
Type of Serological Test RDT, prescreen step
Authors/Company Sensing self
Description This is a pre-screening, at home test (though not authorized for at-home use yet). It tests for IgG and IgM antibodies, and is reported to be 92% accurate.
Phase of development CE certified awaiting FDA EUA.
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date Date not given



Country of development Germany
Type of Serological Test ELISAs
Authors/Company Euroimmun AG
Description This company has two tests, including EI 2606-9601 A, which tests for patient IgA, and EI 2606-9601 G, which tests for patient IgG. The target antigens were not stated, nor were specificity or sensitivity of tests.
Phase of development Research use only, CE/IVD in EU
Proposed release CE/IVD in the EU
Date March 12, 2020



Country of development Germany
Type of Serological Test RDT, lateral flow assay
Authors/Company PharmACT
Description This RDT tests for IgM and IgG of patients, with 92-98% sensitivity in later stages of the infection (day 11-24) with 100% sensitivity.
Phase of development Research use only
Proposed release Appears available for purchase by research labs/healthcare providers, but no clear approvals
Date Date not given



Country of development China
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company Liming Bio
Description COVID-19 IgG/IgM Combo Rapid Test Device is an RDT that tests for patient IgG and IgM antibodies. The sensitivity and specificity for total antibodies were 93.1 and 100%, respectively. For IgG, sensitivity is 82% and specificity is 100%. For IgM, the sensitivity is 62% and specificity is 100%.
Phase of development CE/IVD
Proposed release CE/IVD
Date Feb. 2020



Country of development China
Type of Serological Test Not listed
Authors/Company Snibe Co
Description The company provides two tests the 2019-nCoV IgG , and 2019-nCoV IgM tests. The test is a chemiluminescent immunoassay (CLIA). It has been clinically tested in China, though the exact specificity and sensitivity was not stated.
Phase of development CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date Feb. 19, 2020



Country of development China
Type of Serological Test ELISA
Authors/Company Beijing Wantai
Description They offer, 1. Wantai SARS-CoV-2 Ab Rapid Test Kit, 2. Wantai SARS-CoV-2 IgM ELISA kit, and 3. Wantai SARS-CoV-2 Ab ELISA kit. The kits do not state which antigens are used as targets. 93.1% sensitivity and 100% specificity.
Phase of development Approved for Research use only, unclear if available in the US
Proposed release Released in China
Date Feb. 25, 2020



Country of development China
Type of Serological Test ELISA
Authors/Company Shenzhen Yhlo Biotech Company
Description This company provides 2 tests, the iFlash-SARS-CoV-2-IgG and the iFlash-SARS-CoV-2-IgM, which test for patient antibodies to the virus. The target antigen is not specified. The sensitivity of the IgG assay is over 90%, and specificity is over 95%. For the IgM test, the sensitivity and specificity are both over 95%, based on assaying over 1200 Chinese patient samples.
Phase of development CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date Feb. 27, 2020



Country of development China
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company Sanuo Biotech
Description The SARS-Cov-2 Antibody Test strip tests for patient IgG and IgM. The press release did not disclose sensitivity or specificity of the test.
Phase of development CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers, CE/IVD approved
Date March 12, 2020



Country of development China
Type of Serological Test RDT (colloidal gold lateral flow assay)
Authors/Company BioTime
Description The SARS-CoV-2 IgG/IgM kit tests for patient antibodies to the virus from blood or plasma samples. There is no reported sensitivity or specificity.
Phase of development Only approved for in vitro diagnostic use
Proposed release available for purchase by research labs/healthcare providers
Date Date not given



Country of development The Republic of Korea
Type of Serological Test RDT
Authors/Company GenBody
Description GenBody FIA COVID-19 IgM/IgG (COVI025)
Phase of development Research use only, CE/IVD in EU
Proposed release CE/IVD in the EU
Date March 2, 2020



Country of development United Kingdom
Type of Serological Test RDT
Authors/Company Mologic
Description Seems to be an RDT (probably to IgM and IgG). No description was given, other than 3.5 million tests were ordered.
Phase of development UK has purchased 3.5 million, they are validating now with Liverpool Trop Med and St. Georges, London
Proposed release Date not given
Date March 29, 2020



Country of development China
Type of Serological Test RDT
Authors/Company Livzon Diagnostics
Description RDT, lateral flow assay, which detects IgM and IgG to the nucelocapside protein of SARS-CoV-2.
Phase of development Research use only, CE/IVD approved
Proposed release available for purchase by research labs/healthcare providers
Date Date not given



Country of development USA
Type of Serological Test Not stated, seems to be ELISA
Authors/Company Emory University
Description Emory University has developed a serological test for COVID-19. Details of the test, such as method, target antigen, and antibody type are not listed. The Clinical Immunology section of Emory Medical Laboratories (EML) plans to begin testing 300 people per day, scaling up to 5000 tests per day by June. They state that it will take one vial of blood.
Phase of development Research use only, approved under FDA Policy for Diagnostic Tests for Coronavirus Disease-2019 Section IV.A
Proposed release April 2020
Date April 13, 2020



Country of development USA
Type of Serological Test RDT
Authors/Company Confirm Biosciences
Description This RDT detects IgM and IgG, though the target antigen is unclear. Sensitivity appears to be 93.8%, and sensitivity is 99.1%, in 704 samples tested. The location of the trial was not disclosed.
Phase of development Research use only, not approved by the FDA
Proposed release Available for purchase by research labs/healthcare providers
Date April 15, 2020





Tests that are still in development
Country of development US
Type of Serological Test CRISPR-based lateral flow assay
Authors/Company Broughton et al (Mammoth Biosciences)
Description Using a CRISPR-Cas12 based method, they can specifically detect virus RNA for the E and N genes. This is called the DETECTR assay, and does not assay for patient antibodies, but the presence of viral RNA. The CRISPR-Cas12 RNA targeting is followed by isothermal amplification of the target, resulting in a visual readout with a fluorophore.This was 90% sensitive and 100% specific.
Phase of development Pre-clinical
Proposed release In development
Date March 10, 2020



Country of development US
Type of Serological Test Not stated
Authors/Company CDC
Description They are now beginning testing in specific populations, 1) people who have not been diagnosed but live in a COVID-19 hotspot, 2) a later national survey, and 3) populations like healthcare workers.
Phase of development Clinical
Proposed release Not given
Date April 4, 2020



Country of developmentU US
Type of Serological Test ELISA
Authors/Company Amanat et al.
Description An ELISA based method using recombinant receptor binding domain (RBD) regions of the spike protein or the full length spike protein. COVID-19 patient sera was most reactive to the full length spike protein, while non-COVID-19 patient sera did not react to either protein above background
Phase of development Pre-clinical
Proposed release Not stated
Date March 18, 2020



Country of development US
Type of Serological Test Proprietary
Authors/Company United Biomedical (UBI)/ c19
Description This kit is being tested in a small community in Colorado, in partnership with the Public Health Department of San Miguel County, to test all residents for a SARS-Cov-2 antibody. The assay is testing for antibodies to recombinant fragments of the S, N, and M proteins. So far, the test has 100% sensitivity and specificity after day 10 of symptoms, according to their website. This has not been approved by the FDA. They also state that "Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E"
Phase of development In testing in San Miguel, CO
Proposed release Ongoing trials in Colorado, no stated release date
Date March 19, 2020



Country of development Netherlands
Type of Serological Test ELISA
Authors/Company Okba et al
Description Modifying existing beta version ELISA kits (EUROIMMUN Medizinische Labordiagnostika AG) for IgG or IgA, and an in-house ELISA kit, they coated plates with recombinant S1 domain of the spike protein. The commercially available kits are not yet approved for use. They found that the kits were sensitive and specific for the S1 region of SARS-CoV-2, looking at 45 samples overall.
Phase of development Pre-clinical
Proposed release Not stated
Date March 20, 2020



Country of development China
Type of Serological Test RDT
Authors/Company Jiangsu bioPerfectus technologies
Description This company has two tests, the PerfectPOC Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit and the PerfectPOC Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit. The IgM/IgG test assays for patient antibodies to the virus from a blood sample, while the Ag Rapid test assays for SARS-CoV-2 antigen from nasal swab samples.
Phase of development Developed, awaiting approval
Proposed release Appears available for purchase by research labs/healthcare providers in China, but no clear approvals
Date March 3, 2020



Country of development China
Type of Serological Test RDT
Authors/Company Wuhan EasyDiagnosis Biomedicine Ltd
Description The SARS-CoV-2 IgM/IgG Antibody test kit uses blood or plasma samples to detect patient antibodies. There is no listed sensitivity or specificity
Phase of development No clear approvals
Proposed release available for purchase by research labs/healthcare providers, but no clear CE or FDA approvals
Date Date not given



Country of development Belgium
Type of Serological Test Dipstick (lateral flow assay)
Authors/Company Coris Bioconcept
Description This lateral flow assay detects SARS-CoV-2 antigen in nasal mucus samples. The sensitivity was approximately 60% when tested in two different hospitals.
Phase of development Clinically testing
Proposed release available for purchase by research labs/healthcare providers, does not appear to have any approvals
Date March 24, 2020



Country of development US
Type of Serological Test ELISA
Authors/Company Vitalant/UCSF
Description It appears that Vitalant (a blood donation company) and UCSF have teamed up to make an in-house antibody test for SARS-CoV-2. It is an ELISA based assay, though they have not disclosed which antibodies are detected.
Phase of development In development
Proposed release Date not given
Date March 31, 2020



Country of development US
Type of Serological Test ELISA
Authors/Company Klein lab, JHSPH
Description They have adapted an ELISA, based on Amanat et al 2020, that tests for IgG and IgM to the full length Spike protien and to the receptor binding domain (RBD). They are now working to get a mucosal IgA ELISA working. So far, they are using the kit to test samples from Johns Hopkins Hospital.
Phase of development Pre-clinical
Proposed release Not given, but being used for research use
Date April 6, 2020



Country of development China
Type of Serological Test ELISA
Authors/Company Zhang et al
Description This group developed an in-house ELISA testing for patient antibodies (IgM and IgG) to the SARSr-CoV Rp3 nucleocapside (N) protein. They found that on day 5, 81% of patients were positive for IgM and 100% were positive for IgG (of 16 COVID-19 positive patients).
Phase of development Pre-clinical
Proposed release Not given
Date February 17, 2020



Anti-Capitalist Chronicles: Collective Form of Action




https://www.youtube.com/watch?v=ySH1qEudr50&feature
























A message to all on the occasion of Greek Easter







by Yanis Varoufakis


Today, on the Thursday symbolising the Last Supper, it is hard for Greeks to take their minds off last Thursday, 9th of April 2020 – the day that the Eurogroup shamelessly condemned our long-suffering people, along with millions of Italians and millions of other Europeans, to huge new austerity precisely at the time they will be struggling to recover from lockdown and massive economic depression.
Dark days are coming for our People, our Democracy, for the whole of Europe. The answer must be Calm Unity and Fierce Struggle.
But not yet. Let’s begin after Easter.
Today, the symbolism of the day, for both believers and atheists, is important. It marks the beginning of the crescendo of a week that our tradition has enabled us to use as a poignant reminder that:

Darkness cannot defeat Darkness; only Light can

This miracle happens during the night’s darkest moment

For this miracle to happen, the virtuous must be crucified side-by-side with the thieves
Happy Easter and Carpe DiEM25



How Do Scientists Classify Planets? (Accessible Preview)




https://www.youtube.com/watch?v=6iquzCGzgik